Home -> Law Blog Directory -> Personal Injury Law Blogs -> A Georgia Lawyer
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Personal Injury Law
: A Georgia LawyerGeorgia: Avandia Study
A new study that compares Aandia with Actos found an increased risk of various cardiovascular problems with Avandia, but the studay that hasn?t raised as many concerns.
The authors looked at records of 227,571 Medicare patients with an average age of 74.4 years who were followed for up to three years after starting either of the two pills. What was found? Avandia increased the risk of stroke by 27 percent; heart failure by 25 percent; death by 13 percent; acute myocardial infarction or death by 11 percent; AMI, stroke, or death by 14 percent and AMI, stroke, heart failure or death by 17 percent.
The drug's maker has said about the study: ?it is unclear whether this study has been peer reviewed, and until then, it would be premature to comment. However, it is important to note that there are inherent limitations with retrospective observational studies?Randomized clinical trials remain the gold standard?Results from six randomized clinical trials?show that Avandia does not increase the overall risk of heart attack, stroke or death."
Source here.
Full post as published by A Georgia Lawyer on June 23, 2010 (boomark / email).
Avandia
alleging heart attacks, increased fracture risk that may have been caused by Avandia.
GNG Marketing Violations
Georgia Natural Gas to pay customers $2.5 million in settlement.
Procrit
Associated with Death in Stroke Study
Xigris
Study Prompts FDA Safety Review
BPA
New Study Shows Link to Diabetes and Heart Disease
New Study Links Cell Phone Radiation to Increased Health Risks
Cell Phone Radiation Is Your Phone Toxic?

Avandia Heart Attack: Questions Still Remain
For the RECORD, Many Say Avandia Study is Flawed
Study Links Avandia to Liver Failure
Avandia Heart Attack Risk, Questions Remain
New Study Suggests Avandia Worse than Actos, Glaxo Cries Foul









